Compound Detail
CHEMBL46740
BAZEDOXIFENE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL46740 |
| Name | BAZEDOXIFENE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | UCJGJABZCDBEDK-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
13
Targets
27
Activities
1
Assay Types
15
PK Parameters
20
Publications
4
Known Names
5
Indications
Molecular Properties
470.6
MW (Da)
6.33
ALogP
5
HBA
2
HBD
57.9
PSA (Ų)
0.33
QED
1
Ro5 Violations
7
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2009 |
| Availability | Prescription |
| Chirality | Achiral |
Indications
Menopause Osteoporosis Breast Neoplasms Carcinoma, Intraductal, Noninfiltrating Osteoporosis, Postmenopausal
ATC Classification
G03XC02
bazedoxifene
Level 1: GENITO URINARY SYSTEM AND SEX HORMONES
Level 2: SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Activity Summary
IC50 27 meas. best 9.4
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| MCF7 CHEMBL387 | IC50 | 9.4 | 7.27 | 0.4 | 2 |
| Estrogen receptor CHEMBL206 | IC50 | 9.22 | 7.3125 | 0.6 | 8 |
| Estrogen receptor beta CHEMBL242 | IC50 | 8.42 | 7.4967 | 3.8 | 3 |
| Zaire ebolavirus CHEMBL4513181 | IC50 | 5.65 | 5.65 | 2240.0 | 1 |
| MDA-MB-468 CHEMBL614335 | IC50 | 5.5 | 5.5 | 3140.0 | 1 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 5.46 | 5.46 | 3440.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 5.46 | 5.105 | 3430.0 | 2 |
| Marburgvirus CHEMBL4296577 | IC50 | 5.42 | 5.42 | 3830.0 | 1 |
| MH60 CHEMBL614350 | IC50 | 5.42 | 5.42 | 3800.0 | 1 |
| MDA-MB-231 CHEMBL400 | IC50 | 5.17 | 5.15 | 6730.0 | 2 |
| NON-PROTEIN TARGET CHEMBL3879801 | IC50 | 5.01 | 4.805 | 9700.0 | 2 |
| T47D CHEMBL614361 | IC50 | 4.85 | 4.815 | 14230.0 | 2 |
| HEK293 CHEMBL614818 | IC50 | 4.42 | 4.42 | 38480.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 71.0 | ng.hr.mL-1 | Rattus norvegicus |
| CL | 17.78 | uL.min-1.(10^6cells)-1 | Homo sapiens |
| CL | 35.48 | uL.min-1.(10^6cells)-1 | Rattus norvegicus |
| CL | 38.02 | mL.min-1.g-1 | Homo sapiens |
| CL | - | mL.min-1.kg-1 | Homo sapiens |
| CL | 4.7 | mL.min-1.g-1 | Homo sapiens |
| CL | 6.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | 29.4 | mL.min-1.g-1 | Homo sapiens |
| CL | 166.0 | mL.min-1.g-1 | Homo sapiens |
| CL | 437.0 | mL.min-1.g-1 | Homo sapiens |
| F | 6.2 | % | Homo sapiens |
| Fu | 0.16 | - | Homo sapiens |
| Fu | 0.38 | - | Homo sapiens |
| Tmax | 2.5 | hr | Homo sapiens |
| Vd | 14.7 | L.kg-1 | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine